CEL-SCI Announces Change of Location to 2020 Annual Meeting of Shareholders
March 30 2020 - 4:05PM
Business Wire
CEL-SCI Corporation (NYSE American: CVM), announced today
that the location of its 2020 Annual Meeting of Shareholders will
be changed and a virtual format via a live online webcast will be
added. The annual stockholders meeting, which was previously
announced in CEL-SCI’s Notice of 2020 Annual Meeting and Proxy
Statement and filed with the Securities and Exchange Commission
(“SEC”) on March 4, 2020, will still be held on April 17, 2020 at
10:30 a.m. ET, but in a hybrid meeting format. Because of the
social distancing requirements and the government imposed limit on
the number of people in any meeting, we strongly encourage you to
attend the meeting through the live online webcast.
Due to the emerging public health impact of the coronavirus
outbreak (COVID-19) and to support the health and well-being of its
employees, shareholders, and the community, the Company has made
the decision to change the location and format of the 2020 Annual
Meeting of Shareholders to a hybrid meeting. The new location of
the upcoming meeting will be 8229 Boone Blvd., Suite 802, Vienna,
VA 22182 and via a live online webcast.
Stockholders of record at the close of business on February 21,
2020 will be able to access the 2020 Annual Meeting webcast online
at http://www.meetingcenter.io/291292248. You will be required to
enter your 16-digit control number provided in your proxy material
and a password. The password for the meeting is CVM2020.
If you hold your shares through an intermediary, such as a bank
or broker, you must register in advance to attend the Annual
Meeting online. To register you must submit proof of your proxy
power (legal proxy) reflecting your CEL-SCI holdings along with
your name and email address to Computershare. Requests for
registration must be labeled as “Legal Proxy” and be received no
later than 5:00 p.m., ET, on April 12, 2020. Forward the email from
your broker, or attach an image of your legal proxy, to
legalproxy@computershare.com. You will receive a
confirmation email from Computershare of your registration.
Please note that the proxy card included with the proxy
materials previously distributed will not be updated to reflect the
change in location and may continue to be used to vote your shares
in connection with the Annual Meeting.
If you have already voted your shares, and you do not want to
change your vote, there is nothing further you need to do and your
vote will be counted at the meeting. We encourage you to attend the
annual meeting via the webcast. Geert Kersten, the Company’s Chief
Executive Officer, will be presiding at the annual meeting and
expects to answer questions submitted by shareholders.
About CEL-SCI Corporation
CEL-SCI is a clinical-stage biotechnology company focused on
finding the best way to activate the immune system to fight cancer
and infectious diseases. The Company’s lead investigational therapy
Multikine is currently in a pivotal Phase 3 clinical trial
involving head and neck cancer, for which the Company has received
Orphan Drug Status from the FDA. The Company’s LEAPS technology is
being developed for rheumatoid arthritis and as a potential
treatment of COVID-19 in hospitalized patients. The Company has
operations in Vienna, Virginia, and near Baltimore, Maryland.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, including statements with respect to Multikine and the
Phase 3 clinical trial of Multikine in patients with advanced
primary squamous cell carcinoma of the head and neck. When used in
this press release, the words "intends," "believes," "anticipated,"
"plans" and "expects," and similar expressions, are intended to
identify forward-looking statements. Such statements are subject to
risks and uncertainties that could cause actual results to differ
materially from those projected. Factors that could cause or
contribute to such differences include, an inability to duplicate
the clinical trials or nonclinical results demonstrated in clinical
studies, timely development of any potential products that can be
shown to be safe and effective, receiving necessary regulatory
approvals, difficulties in manufacturing any of the Company's
potential products, inability to raise the necessary capital and
the risk factors set forth from time to time in CEL-SCI's filings
with the Securities and Exchange Commission, including but not
limited to its report on Form 10-K/A for the year ended September
30, 2019 and its recently filed prospectus supplement. The Company
undertakes no obligation to publicly release any revision to these
forward-looking statements which may be made to reflect the events
or circumstances after the date hereof or to reflect the occurrence
of unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200330005626/en/
Gavin de Windt CEL-SCI Corporation (703) 506-9460
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Sep 2023 to Sep 2024